GlassScriptPhysician profile
Patrick Lee Nettles
NPI 1285235457
$3,952.11
in general payments reported to CMS, 2019-2025
23 companies · $687 in 2025
The $687 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $274 · 2022: $807 · 2023: $1,380 · 2024: $804 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,871.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,234.05 | 2021-2025 | |
| Axsome Therapeutics, INC. | $547.48 | 2023-2025 | Auvelity |
| Alkermes, INC. | $162.66 | 2022-2025 | Aristada, Aristada Initio, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $136.54 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $131.58 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $122.40 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.64 | 2023-2025 | Caplyta |
| Novo Nordisk INC | $75.13 | 2023-2025 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $57.77 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Exact Sciences Corporation | $43.55 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $38.55 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $37.22 | 2021-2025 | |
| Lundbeck LLC | $36.72 | 2024-2025 | Rexulti |
| Amarin Pharma, INC. | $36.46 | 2021 | |
| Phathom Pharmaceuticals, INC. | $33.32 | 2024 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $30.37 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Ironshore Pharmaceuticals INC. | $27.64 | 2022-2024 | |
| Dexcom, INC. | $27.55 | 2021-2023 | Dexcom G6 Transmitter |
| Stryker Corporation | $18.16 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $17.64 | 2024 | Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $15.69 | 2024 | Farxiga |
| Medtronic, INC. | $15.34 | 2025 | Intellis Adaptivestim |
| Bausch Health US, LLC | $14.65 | 2023 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Nettles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.